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Abstract. It has been recently reported that phenyl- 
methanesulfonyl fluoride (PMSF) when given to hens after 
a neuropathic organophosphate (OP) promotes organo- 
phosphate-induced delayed polyneuropathy (OPIDP). 
Chicks are resistant to OPIDP despite high inhibition/aging 
of neuropathy target esterase (NTE), the putative target of 
0PIDP initiation. However, when PMSF (300 mg/kg s.c.) 
is given to chicks after di-butyl 2,2-dichlorovinyl 
phosphate (DBDCVP, 1 or 5 mg/kg s.c.), OPIDP is pro- 
moted. Inhibition/aging of at least 30% of NTE was 
thought to be an essential prerequisite for promotion to be 
elicited in adult hens. However, we observed in hens that 
when NTE is maximally affected (>90%) by phenyl N- 
methyl N-benzyl carbamate (40 mg/kg i. v.), a non-ageable 
inhibitor of NTE, and then PMSF is given (120 mg/kg/day 
s.c. x 3 days) clinical signs of neuropathy become evident. 
Methamidophos (50 mg/kg p.o. to hens), which produces 
in vivo a reactivatable form of inhibited NTE, was shown 
either to protect from or promote OPIDP caused by 
DBDCVP (0.45 mg/kg s. c.), depending on the sequence of 
dosing. Because very high doses of methamidophos cause 
OPIDP, we considered this effect to be a "self-promoted" 
OPIDP. We concluded that NTE inhibitors might have 
different intrinsic activities for producing OPIDP once 
NTE is affected. Aging might differentiate highly neuro- 
pathic OPs, like DBDCVP, from less neuropathic OPs, like 
methamidophos, or from the least neuropathic carbamates, 
which require promotion in order for neuropathy to be 
expressed. Retrograde axonal transport in motor fibers was 
measured as the accumulation of 125 I-tetanus toxin in spi- 
nal cord after injection in the gastrocnemius muscle of 
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chicks treated either with DBDCVP (5 mg/kg s.c.) or with 
DBDCVP followed by PMSF (300 mg/kg s.c.). Retro- 
grade axonal transport was reduced in both groups (to 
about 50%, 10 days after dosing) and returned to normal 
27 days after dosing. However, DBDCVP-treated chicks 
had a mild neuropathy which recovered relatively quickly, 
whereas chicks to which PMSF was also given had more 
severe signs which did not recover by day 27. We 
concluded that promotion affects a site other than NTE and 
that it acts at a point downstream from initiation. 
PMSF was also shown to promote 2,5-hexanedione 
(2,5-HD) neuropathy. 2,5-HD was given to hens at 
doses (200 mg/kg/day i.p. x 8 days) which caused 
mild and reversible neuropathy. When PMSF 
(120 mg/kg/day • 2 days at the end of 2,5-HD treatment) 
was given, more severe and irreversible signs of neuropa- 
thy were observed. We conclude that promotion might be a 
common feature in neuropathies of different origin. 
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Introduction 
Phenylmethanesulfonyl fluoride (PMSF) is an inhibitor of 
proteases and esterases (Prouty and Goldberg 1972) with 
low cholinergic toxicity. PMSF has been used in mechanis- 
tic studies of organophosphate-induced delayed poly- 
neuropathy (OPIDP) because it protects hens from this 
toxicity (Johnson 1982). When neuropathy target esterase 
(NTE), the putative target for the initiation of OPIDP, is 
sulfonylated in vivo byPMSF prior to neuropathic doses of 
organophosphates (OPs), no OPIDP develops (Johnson 
1974; Lotti et al. 1987). PMSF shares this effect with other 
NTE inhibitors, e. g., some phosphinates and carbamates. It 
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is thought  that OPIDP  develops when enough N T E  (>70%) 
is modif ied by a two-step mechanism, involving inhibition 
o f  the enzyme  and a subsequent intramolecular  rearrange- 
ment called "aging" (Johnson 1982). Protection occurs 
because sulfonylated, phosphinylated and carbamylated 
NTEs are not able to undergo the "aging" reaction (John- 
son 1982). Consequently,  by occupying  N T E  in a non-age-  
able form they prevent the phosphorylat ion/aging of  N T E  
by neuropathic UPs. 
However ,  it has been shown recently that when P M S F  
or other non-ageable inhibitors are given after a neuropath- 
ic UP they promote O P I D P  (Pope and Padilla 1990; Lotti  
et al. 1991). Thus tar promotion was caused only by non- 
ageable NTE inhibitors at doses which were inhibitory to 
N T E  (when given to naive birds), and when about 30% of  
NTE was affected by the initiating UP (Lotti et al. 1991). 
We  report in this paper  further studies aimed at under- 
standing the significance o f  promotion.  In particular, we 
addressed some known exceptions in OPIDP  to determine 
whether they remain as such when promotion is given. 
Thus, we observed that P M S F  promotes OPIDP  in chicks, 
which are known to be resistant to this toxicity (Johnson 
and Barnes 1970). Age-related resistance occurs despite 
the high inhibition/aging of  NT E  in the nervous tissues o f  
young  animals (Moretto et al. 1991), even though it can be 
partially overcome by increasing the single dose o f  the 
neuropathic UP (Peraica et al. 1991). 
A notable exception as far as aging is concerned has 
been recently reported. Methamidophos  (O,S-dimethyl  
phosphorothioamidate)  causes OPIDP  in the hen at ex- 
ceedingly high doses but inhibited brain N T E  can be fully 
reactivated by KF, suggesting that aging had not occurred 
(Johnson et al. 1991). We  report in this paper another 
exception o f  this type. High doses o f  phenyl N-methyl  
N-benzyl  carbamate (PMBC),  which caused high levels of  
non-ageable carbamylated NTE, produced neuropathy in 
hens only when a subsequent promot ing dose o f  P M S F  was 
given. Just as P M B C  can both protect and promote neuro- 
pathy (Lotti et al. 1991) methamidophos  was also found to 
cause both protection and promot ion in hens, depending on 
the sequence o f  dosing with a neuropathic UP. 
The results o f  these experiments on exceptions in 
OPIDP  indicate that the mechanism o f  promotion might  be 
different f rom that o f  initiation. This contention was sup- 
ported by the fol lowing findings. 
First, retrograde axonal transport, which is selectively 
reduced in OPIDP  (Moretto et al. 1987), was not affected 
by promotion when assessed in young  chicks. 
Second, the peripheral neuropathy caused by 2,5- 
hexanedione (2,5-HD), which has a different mechanism 
of  initiation f rom that o f  O P I D P  (DeCaprio 1987), but also 
proceeds with a reduction o f  retrograde axonal transport 
(Braendgaard and Sidenius 1986), was also promoted by 
P M S F  in hens. 
Materia ls  and methods  
Chemicals. Acetonylacetone (2,5-hexanedione; 2,5-HD), 97% purity and 
atropine sulfate were purchased from Aldrich-Chemie, Steinheim, FRG. 
O,S-dimethyl phosphorothioamidate (methamidophos) was purchased 
from Societa' Italiana Chimici, Rome, Italy. Phenylmethanesulf0n! 
fluoride (PMSF) and diisopropylphosphorofluoridate (DFP) were p~ 
chased from Fluka AG Chem. Fabrik, Buchs, Switzerland. Phenyl~, 
methyl N-benzyl carbamate (PMBC) was purchased from the Medicz 
Research Council, Carshalton, UK. Di-butyl 2,2-dichlorovinyl phospht 
(DBDCVP) was purchased from Ash Stevens, Detroit, MI, USA. Dieth, 
p-nitrophenyl phosphate (paraoxon) was purchased from Sigma Che~ 
cal Co., St Louis, MO, USA. Phenyl valerate and N,N'-diisopr0p'. 
phosphorodiamidofluoridate were purchased from Lark Enterprise, 
Webster, MA, USA. Tetanus toxin was kindly supplied by Dr. Mon~ 
cucco, Dept of General Pathology, University of Padua and N-succi~ 
midyl 3-(4 hydroxy-5-[ 125 I]-iodophenyl) propionate was purchase 
from Amersham, UK. 
Animals. Randomly bred adult hens (1.7-2.7 kg body wt) and Warz 
strain female chicks (36-40 days of age) were purchased from a Ic~ 
breeder, caged in groups of five to ten, and allowed food and watera 
libitum. 
All chemicals given to animals were dissolved immediately bef0I 
administration in glycerol formal (Fluka) except methamidophos a~ 
2,5-HD, which were dissolved in water. Pretreatment with atropine s~ 
fate (20 mg/kg i.p.) to counteract cholinergic toxicity was given in/ 
experiments, except in those with 2,5-HD, DBDCVP (1 mg/kg)ar~ 
PMSF. Maximal volumes used were the following: 0.5 ml/kg p.c 
1.5 ml/kg s.c., 1.0 ml/kg i.p., and 0.13 ml/kg i.v. 
Clinical signs of ataxia were evaluated on a 0 -  8 point scale acc0rl 
ing to Lotti et al. (1991). 
Animals were killed by decapitation and brain, lumbosacral spie, 
cord and sciatic nerve were excised immediately and either placedi 
ice-cold 50 mM TRIS-HCI buffer (pH 8.0 at 23 ~ C) containing 0.2 r~ 
EDTA and assayed for NTE or stored at -80 ~ C prior to assay. 
NTEassays. NTE was measured in the brain according to Johnson (197" 
and in the peripheral nerve according to Caroldi and Lotti (1982)z 
modified by Muretto et al. (1989). NTE activities of control hens wet 
always within the range of historical values from our laboratory: 2.0-2: 
in brain, 0.5- 0.7 in the spinal cord and 0.1 - 0.15 in the peripheral nen 
(gmol/min/g wet wt of tissue). 
Retrograde axonal transport. Retrograde axonal transport was measu~ 
in motor fibers of sciatic nerve of chicks as the accumulation of 1251E 
the spinal cord 28 h after injection of labelled tetanus toxin into 
gastrocnemius muscle according to Moretto et al. (1987). 125 I tetant 
toxin was prepared according to Rogers and Snyder (1981). The specific 
ity of iodination was checked by autoradiography of a gel electroph0r~ 
togram of the eluate containing high radioactivity. 
Animals were injected with 125 I-tetanus toxin 5, 10, and 27 da~ 
after the treatments. 
Results  
The promoting effect of  PMSF in chicks is shown i~ 
Table 1. D B D C V P  (1 mg/kg s.c) and DFP (1.5 mg/kg s.c, 
failed to cause O P I D P  when given alone, but promoti0~ 
occurred when PMSF was given afterwards. However 
mild OPIDP  was observed with a higher dose o f  DBDC~ 
(5 mg/kg  s.c.), which was also promoted by subsequent! 
administered PMSF.  The promoting effect o f  PMSF wa, 
stronger in DFP-treated chicks (clinical score increasei 
f rom 0 to 5.1) than that in DBDCVP-t rea ted  chicks (clini 
cal score increased f rom 1.8 to 5.1). 
Table 2 shows that when P M B C  was used instead of~ 
OP to "initiate OPIDP" ,  then clinical neuropathy occurre~ 
after P M S F  treatment. However ,  when the sequence 0i 
dosing o f  the same compounds  was reversed, a margini 
response was observed in two animals only. 
Table 1. OPIDP promotion by PMSF in chicks a 
Initial dosing PMSF b Clinical score c 
(mg/kg s.c.) (300 mg/kg s.c.) (mean • SD) 
DBDCVP (1) d Solvent 0 (5) 
DBDCVP (1) + 2.0• 1.4 (4) 
DBDCVP (5) Solvent 1.8• 1.3 (12) 
DBDCVP (5) + 5.1 __. 1.5 (10) 
DFP (1.5) e Solvent 0 (8) 
DFP (1.5) + 5.1 +__ 1.3 (8) 
39 days of age at the beginning of the experiment 
b Given 24 h later. This dose does not cause OPIDP and inhibits more 
than 90% of brain NTE (Lotti et al. 1991) 
c Maximal scores are reported and were reached 12-15 days from the 
beginning of the experiments. Number of animals in brackets 
a This dose given to 20-day-old chicks causes about 80% NTE inhibi- 
tion in peripheral nerve (Moretto et al. 1991) 
This dose given to 36-day-old chicks causes 70 _+ 11% NTE inhibition 
in peripheral nerve (n = 3; mean • SD; activity of control was 
1.71 + 0.06 nmol/min/mg of protein) 
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Table 2. Promotion of neuropathy in hens treated with a combination of 
PMSF and PMBC 
Dosing Clinical score 
PMBC (40 mg/kg i.v. x 3)" 
PMSF ( 120 mg/kg s.c. x 3) b 
PMBC (40 mg/kg i. v.) c + PMSF 
( 120 mg/kg s.c. x 3) a 
PMSF (120 mg/kg s.c. x 3) + PMBC 





a Treatments were given 5 h apart. In one animal killed 7 h after the last 
dose, brain NTE activity was 93% inhibited 
b Treatment was given 12 h apart. In one animal killed 24 h after the last 
dose, brain and peripheral nerve NTE activities were 98% and 88% 
inhibited, respectively. PMSF ( 120 mg/kg s. c.) caused about 93% inhibi- 
tion of brain NTE when measured 24 h after treatment (Lotti et al. 1991 ). 
No ataxia was observed when either a single dose of 480 mg/kg s. c. or 9 
daily doses of 30 mg/kg s. c. of PMSF were given 
c PMBC (40 mg/kg i. v.) causes 80-90% inhibition of brain NTE (Lotti 
et al. 1991) when measured 5 h after treatment 
d Given 5, 17, and 29 h after PMBC 
r Given 24 h after the last dose of PMSF 
Table 3. Promotion of and protection from DBDCVP neuropathy by methamidophos in hens 
Dosing (mg/kg) a Clinical score % NTE activity b 
mean • SD (n) 
Brain Spinal cord Peripheral nerve 
DBDCVP (0.45 s.c.) 3.1 + 1.4 (9) 
DBDCVP (0.45 s. c.)+ methamidophos (50 p.o.) 6.2 • (5) 
Methamidophos (50 p.o.) 0 (3) 
Metbamidophos (50 p. o.)+ DBDCVP (0.45 s.c.) 0 (4) 
Methamidophos (25 p. o.) 
Methamidophos (25 p. o.)+ DBDCVP (0.45 s.c.) 4.3 _+0.6 (3) 
Methamidophos (5 p. o.) 
Melhamidophos (5 p. o.)+ DBDCVP (0.45 s.c.) 4.6 • 1.1 (3) 
10• l c 17• c 46• c 
8 12 12 
50 52 45 
12 12 24 
76 73 73 
83 67 100 
a Treatments were given 24 h apart 
b Measured 24 h after last dosing. Expressed as percentage of NTE activity of a concurrent control. Control activity was within historical values from 
our laboratory (see Materials and methods) 
c Data from Moretto et al. (1989) 
Table 3 shows that methamidophos (50 mg/kg p.o.) 
both protected from and promoted D B D C V P  neuropathy,  
depending on the sequence of dosing. However,  lower 
doses of methamidophos given prior to D B D C V P  failed to 
protect birds, because most  of the NTE activity was left for 
phosphorylation by DBDCVP.  The severity of OPIDP in 
such birds was not different f rom that seen in birds treated 
with DBDCVP only. 
Figure ! shows the clinical effects of D B D C V P  and of 
DBDCVP fol lowed by P M S F  in chicks, together with the 
reduction of retrograde axonal  transport. D B D C V P  caused 
a mild and reversible OPIDP,  whereas when PMSF was 
also given, birds were more severely affected and recovery 
was much delayed. In  contrast with these t ime-courses of 
clinical effects, the accumula t ion  of 125 I-tetanus toxin 
showed a progressive reduct ion and then a full recovery in 
both groups. 
Figure 2 shows the promot ing effect of  P M S F  when 
given after repeated doses of 2,5-HD which caused on its 
own a mild neuropathy in some hens only. PMSF exacer- 
bated the severity of signs, caused all animals  to be af- 
fected, and delayed the recovery. 
Discussion 
OPIDP promotion by PMSF was shown in the hen after OP 
doses which do not cause overt clinical signs (Pope and 
Padilla 1990; Lotti et al. 1991). This effect was conf i rmed 
in chicks but it is different in as much as promot ion  over- 
comes their resistance to OPIDP whereas in hens causes a 
"subthreshold" inhibi t ion/aging of N TE to be expressed 
clinically (Lotti et al. 1991). Because maximal  inhibi-  
t ion/aging of NTE in chicks is not enough to tr igger cl inical  
OPIDP (Moretto et al. 1991), they might differ f rom the 
hen either because of  lack of progression of the lesion or of  
a more efficient repair. Consequent ly ,  promotion by P M S F  
in chicks should affect one or both of these functions,  
which seem unrelated to NTE. 
Promotion caused clinical responses of s imilar  size in- 
dependent ly from the initial effect of different compounds .  
In fact, the clinical score was higher in chicks treated with 
DBDCVP (5 mg/kg) than that in birds treated with DFP, 
whereas after PMSF it was the same in both groups. A 
similar phenomenon  was observed when promot ion  was 
given to chicks of different age (Peraica et al. 1991; Pope 
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Fig, 1. Effects on clinical behavior and retrograde axonal transport 
(R. A. 7".) in motor fibers of sciatic nerve, in chicks treated with 
DB DCVP alone ( [] ) and in combination with PMSF ( ~ ) .  Fifty chicks of 
40 days of age were injected with DBDCVP (5 mg/kg s. c.) after pretreat- 
ment with atropine and 24 h later either with solvent or with PMSF 
(300 mg/kg s.c.). 125 I-tetanus toxin was injected on days 5, 10 and 27. 
Data are expressed as mean percentage ( 4- SE) of the mean of controls. 
The same preparation of 125 I-tetanus toxin was used on days 5 and 10 but 
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differently diluted. Control values for ]25 l-accumulation were~ 
d a y S = 5 6 9 8 + 7 3 8  CPM (mean -4- SD, 8 animals), on day 10 
3 8 3 4 +  1277 CPM (g animals) and on day 27 = 17124-496 CPM (7~ 
mals). * Significantly different from controls and day 27, by one-N: 
analysis of variance (Kruskal-Wallis test, p <0.05). t Significa~ 
different from animals treated with DBDCVP only, Wilcoxon 
(p <0.001) 
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Fig. 2. Development of 2,5-HD neuropathy ( [] ) in hens (200 mg/kg i.p. x 8 daily) and the influence of two subsequent doses of PMS F ( 120 mg/kg s.~ 
daily) ( []  ). Two birds dosed with PMSF prior to 2,5-HD had mild neuropathy with a time course similar to that in birds treated with 2,5-HD only 
and Padilla 1991). Indeed, regardless of  age susceptibility 
to OPs, PMSF promoted OPIDP to a similar degree of 
severity. These observations imply either a maximal pro- 
moting effect, or that phosphorylated NTE at different ages 
or with different OPs varies in its capability to initiate 
OPIDP, or both. Besides their inhibitory power, NTE in- 
hibitors might therefore display different intrinsic activities 
with respect to initiation of  OPIDP, once attached to NTE. 
Thus, PMSF promotion may represent a combination of 
different degrees of  OPIDP initiation plus the same maxi- 
mal promoting effect. 
The hypothesis that NTE inhibitors might have different 
intrinsic activities (Lotti et al. 1991) is supported by results 
on PMBC and methamidophos. N-Methyl N-benzyl car- 
bamylated NTE does not age (Johnson 1982) and con- 
sequently no neuropathy develops when this compound is 
given on its own. However,  PMBC becomes neuropathic 
when PMSF treatment follows. Methamidophos causes 
OPIDP at very high doses when almost all NTE is affected 
in a non-ageable form (Johnson et al. 1991 ). When given at 
lower doses it protects from and promotes DBDCVP neu- 
ropathy, depending on the order of  dosing. Looking at NTE 
as a receptor, inhibitors will behave like partial agonists 
(such as PMBC and methamidophos, causing protection or 
weak initiation) or like full agonists (such as DBDCVP, 
causing neuropathy), where the capability to age would 
confer the property of  a full agonist. Therefore, PMBC 
neuropathy is expressed only by PMSF promotion, where- 
as methamidophos neuropathy is "self-promoted" when 
exceedingly high doses are given. OPIDP in resistant 
chicks caused by very high doses of OPs (Peraica et ai. 
1991) may also be interpreted as "self-promotion". 
Promotion has no effect on retrograde axonal transport, 
because the clinical scores of DBDCVP-treated chicks are 
less severe than those of chicks treated also with PMSF, 
whereas the reductions of  retrograde axonal transport are 
similar in the two groups. Because reduction of retrograde 
axonal transport is involved in the pathogenesis of OPIDP 
(Moretto et al. 1987) measurement of retrograde axonal 
transport might discriminate between progression of the 
lesion and other mechanisms affecting the clinical out- 
come. 
Given the results of  NTE inhibition in the hen after 
much smaller doses of  DBDCVP (Moretto et al. 1987) we 
might assume that almost all NTE was inhibited in chicks 
by DBDCVP before PMSF was given. Taking into account 
also methamidophos (Johnson et al. 1991) and PMBC data 
where promotion occurred after maximal NTE inhibition, 
we conclude that NTE is probably not the target of promo- 
tion. 
The mechanism of  2,5-HD neuropathy is thought to 
involve the formation of adducts to ~-amino groups of 
lysine residues in subunit proteins of neurofilaments and 
subsequent crosslinking (DeCaprio 1987). Because this 
target is different from that of  OPIDP and yet PMSF pro- 
motes both neuropathies, promotion must act at a point in 
common downstream from initiation. It is possible that 
neuropathies produced by different means will also be 
promoted by PMSF. 
In conclusion, these experiments suggest that the aging 
of inhibited NTE is not necessary to initiate neuropathy. 
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However, the initiation of  neuropathy correlates with NTE 
inhibition, lnhibitors might have a very low intrinsic activ- 
ity (PMSF < PBMC < methamidophos) or high intrinsic 
activity (DFP <DBDCVP), once they are attached to NTE. 
The aging reaction might differentiate full agonists from 
others. Promotion seems to be separate from progression of  
the initial lesion and to reach a maximum effect. Perhaps 
promotion involves a mechanism of either degeneration in 
the cascade of events which tbllow initiation and/or repair 
common to all degenerating axons. It also appears that 
promotion affects a site other than NTE, although it has to 
be explained why, so far, only NTE inhibitors act as pro- 
moters (Lotti et al. 1991 ). 
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